Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.55 |
| ▸ | EDNRA | P25101 | 9/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065399 | 0.93 | EDNRB (0.55) | EDNRBEDNRAMCHR1NPC1LMNA | |
| SCHEMBL7068563 | 0.89 | EDNRB (0.53) | EDNRBEDNRAL3MBTL1 | |
| SCHEMBL7069270 | 0.88 | EDNRB (0.51) | EDNRBEDNRAMCHR1LMNASMN1; SMN2 | |
| SCHEMBL7829192 | 0.88 | EDNRB (0.51) | EDNRBEDNRAMCHR1NPC1LMNA | |
| SCHEMBL7069884 | 0.87 | GAA (0.48) | EDNRBEDNRAMCHR1L3MBTL1 | |
| SCHEMBL7065610 | 0.87 | EDNRB (0.47) | EDNRBEDNRAMCHR1LMNAHPGD | |
| SCHEMBL7065442 | 0.85 | ALDH1A1 (0.54) | EDNRBEDNRAMCHR1NPC1LMNA | |
| SCHEMBL7065689 | 0.84 | EDNRB (0.49) | EDNRBEDNRANPC1LMNAHPGD | |
| SCHEMBL7069387 | 0.83 | EDNRA (0.51) | EDNRBEDNRAMCHR1LMNASMN1; SMN2 | |
| SCHEMBL7334893 | 0.83 | EDNRA (0.51) | EDNRBEDNRAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | claimed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885MCHR1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.